

An Updated Review on Drug Regulatory Affairs

Shriniwas Mane, Sanjay K. Bais, Ajay Yedravkar,

Fabtech College of Pharmacy, Sangola, Solapur, Maharashtra, India

Abstract: *The field of regulatory affairs (RA) serves as a link between the global pharmaceutical sector and regulators. It was created in response to governments' desire to safeguard the public's health by regulating the efficacy and safety of pharmaceuticals, veterinary drugs, medical equipment, pesticides, agricultural chemicals, cosmetics, and other goods. Companies that are in charge of the development, manufacture, testing, and sale of these products aim to guarantee that they deliver safe and efficient goods for the welfare of the general public. Different registration criteria for pharmaceutical products are covered by pharmaceutical drug regulatory affairs. As a result of the demand for superior quality medicine that includes safety and efficacy in the areas of not only pharmacy but also veterinary medicine, medical devices, insecticides, pesticides, agrochemicals, cosmetic, and supplementary medicine, a new profession called pharmacy was created. Additionally, it created a connection between the pharmaceutical corporation and the regulating bodies. Maintaining the appropriateness and accuracy of the product information is another duty assigned to it. And its primary responsibility is to serve as a point of contact for regulatory agencies, providing expertise and regulatory intelligence in translating regulatory requirements into realistic, workable plans, and advising the company on regulatory aspects and the regulatory environment that would affect their proposed projects..*

Keywords: CDSCO, NDA, ISO, API, NCE, SDSCO, FAA, ENAC, FSMA, FDA, Ccgmp, ENAC, MAA, ROM, RA

Background: There is still a lack of information on the usage of GLP-1 receptor agonists (GLP-1RA) in individuals with established heart failure (HF).

Methods: Patients with established HF who received GLP-1RA and had at least two visits at Cardiometabolic Center (CMC) between January 2019 and December 2020 were included in the study. Between the baseline and most recent CMC visit, we compared changes in the outcomes of interest.

REFERENCES

- [1]. https://www.topra.org/TOpra/TOpra_Member/What_is_regulatory_affairs.aspx
- [2]. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612334/>
- [3]. <https://cleartax.in/s/drug-license>
- [4]. <https://ipapharma.org/portfolio/regulations-and-guidelines/> 5.
<http://www.reportlinker.com/ci02257/Pharmaceutical.html>
- [5]. <http://www.dra.uni-bonn.de/hoerner>
- [6]. <http://www.pharmatext.org/2008/06/drugs-from-discovery-to-approval.html>
- [7]. Wang H., Wang C., Yu W., Hsu S, Huang Y, Lin Y., Leu Y. And Lee C. From Pharmacovigilance to Pharmacovigilance Planning—The System Building for Safe Medication. J Food Drug Anal. 2007; 15:377-386.
- [8]. <http://www.cdsc.nic.in/forms/list.aspx?lid=1791&Id=1>
- [9]. http://www.cdsc.nic.in/writereaddata/office_order_power_delegation.pdf
- [10]. <http://www.drugs.kar.nic.in/node/203.html>
- [11]. http://www.siroclinpharm.com/siro_pdf/articles/MPH_Jan11_Clinical_Research.pdf
- [12]. <https://globalhealthtrials.tghn.org/community/blogs/post/683/2013/11/clinicaltrialregulation-in-india-recent-updates/>
- [13]. <http://www.veedacr.com/pdf%20documents/Regulatory-Presentation.pdf>

- [14]. S Naralkar, K Karande, P Vasani. The Indian pharmaceutical environment. Regulatory Rapporteur. 2010;7(2):9-10.
- [15]. <http://www.cdscn.nic.in/forms/list.aspx?lid=1584&Id=1>
- [16]. .Regulatory Affairs from Wikipedia, the free encyclopedia modified on 7th April available at
- [17]. http://en.wikipedia.org/wiki/Regulatory_Affairs.
- [18]. International regulatory affair updates, 2005. Available at <http://www.iraup.com/about.php>
- [19]. Douglas J Pisano and David S. Mantus. Text book of FDA Regulatory Affairs A Guide
- [20]. For Prescription Drugs, Medical Devices, and Biologics' Second Edition.
- [21]. Regulatory Affairs brought by learning plus, inc. available at <http://www.cgmp.com/ra.htm>
- [22]. Training Needs in Regulatory Science for the Biopharmaceutical Industry, Nature Jobs 24. Biotechnology, 19(12), 2001, 1187-1188